VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

2008–2009 trivalent influenza vaccine 2011–2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). Afluria Agriflu Fluarix FluLaval FluMist Fluvirin Fluzone Fluzone High-Dose Influenza A (H1N1) 2009 Monovalent Vaccine by Novartis Influenza A (H1N1) 2009 Monovalent Vaccine from Sanofi Pasteur Influenza virus DNA vaccine H5 DNA Influenza virus DNA vaccine HA-DNA Influenza Virus Vaccine H5N1 by Sanofi Pasteur Inc
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Tradename: A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Florida/4/2006; Sanofi-Pasteur
  • Vaccine Ontology ID: VO_0004809
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Human
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004810
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Baboon
  • Immunization Route: Intramuscular injection (i.m.)
  • Product Name: Influenza Virus Vaccine
  • Tradename: Afluria
  • Manufacturer: CSL Limited
  • Vaccine Ontology ID: VO_0000006
  • CDC CVX code: 141, 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License # 1764)
  • Host Species for Licensed Use: Human
  • Antigen: The vaccine is a purified, inactivated, split virion influenza vaccine made by “splitting” the purified, inactivated, whole virus to form fragments. This process reduces the number of adverse events experienced with whole virus vaccines, yet leaves the surface antigens and structural proteins in their original antigenic form. This vaccine includes Influenza virus subtypes A and type B, and is specifically formulated to contain A/California/7/2009 (H1N1), A/Wisconsin/15/2009 (H3N2) and B/Brisbane/60/2008 (B Strain) (FDA: Afluria).
  • Preparation: Afluria is a sterile suspension prepared from influenza virus. The virus is harvested from the allantoic fluid of embryonic chicken eggs, and purified in a sucrose density gradient using a continous flow zonal centrifuge. The purified virus is inactivated with beta propiolactone. The virus particles are disrupted using sodium taurdeoxycholate to produce a "split virion." The disrupted virus is further purified and suspended in a phosphate-buffered isotonic solution (FDA: Afluria).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: ALFURIA in a multi-dose vial should be stored at a temperature of 36 to 46 degrees Fahrenheit. Both the single and multi-dose vials should be shaken thoroughly before administration.
  • Approved Age for Licensed Use: 6 months and older (FDA: Afluria).
  • Contraindication: AFLURIA should not administered to anyone with known hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or in anyone who has had a life-threatening reaction to previous influenza vaccination (FDA: Afluria).
  • Product Name: Influenza Virus Vaccine
  • Tradename: Agriflu
  • Manufacturer: Novartis Vaccines and Diagnostics Inc.
  • Vaccine Ontology ID: VO_0001126
  • CDC CVX code: 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Allergen: Eggs, kanomycin, neomycin
  • Preparation: The trivalent inactivated vaccine consists of virus propagated in the allantoic cavity of embryonated hens’ eggs inoculated with an influenza virus suspension containing kanamycin and neomycin sulphate, which is then filtered and inactivated by treatment with formaldehyde. The surface antigens, hemagglutinin and neuraminidase, are obtained from the influenza virus particle by further centrifugation in the presence of cetyltrimethylammonium bromide (CTAB), a process which removes most of the internal proteins. The CTAB is removed from the vaccine preparation by subsequent purification steps (FDA: Agriflu).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2-8°C
  • Approved Age for Licensed Use: 18 years and older
  • Description: AGRIFLU® is an inactivated vaccine indicated for active immunization for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine (FDA: Agriflu).
  • Product Name: Influenza Virus Vaccine
  • Tradename: Fluarix
  • Manufacturer: GlaxoSmithKline Biologicals
  • Vaccine Ontology ID: VO_0000045
  • CDC CVX code: 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1617) and 98 other countries.
  • Host Species for Licensed Use: Human
  • Antigen: Inactivated split-virion trivalent vaccine consisting of the FDA-recommended strains of influenza A and influenza B viruses for the 2007/2008 flu season.
  • Preparation: FLUARIX is a sterile suspension prepared from influenza viruses propagated in embryonated chicken eggs. Each influenza viruses is produced and purified separately. After harvesting, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration. Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended in sodium phosphate-buffered isotonic sodium chloride solution (GSK: US Fluarix).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Most adverse events in clinical trials were mild and self-limited.
  • Storage: The prefilled syringe should be shaken well before administration. Do not inject intravenously. Store FLUARIX between 2º and 8ºC (GSK: US Fluarix)
  • Approved Age for Licensed Use: Ages 3 and older (FDA: Fluarix).
  • Contraindication: FLUARIX should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to chicken proteins, or to any component of FLUARIX or who has had a life-threatening reaction to previous administration of any influenza vaccine (GSK: US Fluarix).
  • Product Name: Influenza Virus Vaccine
  • Tradename: FluLaval
  • Manufacturer: ID Biomedical Corporation of Quebec
  • Vaccine Ontology ID: VO_0000043
  • CDC CVX code: 141
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1739)
  • Host Species for Licensed Use: Human
  • Antigen: Inactivated influenza virus subtypes A and type B
  • Preparation: FLULAVAL is a trivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza virus strains is produced and purified separately. The virus is inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate (FDA: FluLaval).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: FLULAVAL should be stored between 36 and 46 degrees Fahrenheit. DO NOT FREEZE. The multi-dose vial should be shaken vigorously before each administration.
  • Approved Age for Licensed Use: Ages 18 and older (FDA: FluLaval)
  • Contraindication: FLULAVAL should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to chicken proteins, or to any component of FLULAVAL, or who has had a life threatening reaction to previous influenza vaccination (FDA: FluLaval).
  • Description: FLULAVAL is an inactivated influenza virus vaccine indicated for active immunization of adults (18 years of age and older) against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
  • Product Name: Influenza Virus Vaccine Live, Intranasal
  • Tradename: FluMist
  • Manufacturer: MedImmune Vaccines, Inc.
  • Vaccine Ontology ID: VO_0000044
  • CDC CVX code: 111
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1652)
  • Host Species for Licensed Use: Human
  • Antigen: influenza virus subtypes A and type B. Flumist contains three strains: A/South Dakota/6/2007 (H1N1) (A/Brisbane/59/2007-like), A/Uruguay/716/2007 (H3N2) (A/Brisbane/10/2007-like), and B/Florida/4/2006 (FDA: Flumist).
  • Preparation: Eggs are inoculated with each of the strains and incubated. The fluid of these eggs is harvested, pooled and then filtrated. The virus is ultracentrifugated and diluted with stabilizing buffer. Ethylene diamine tetracetic acid (EDTA) is added to the dilution buffer for H3N2 strains. The viral harvests are then sterile filtered to produce the monovalent bulks. Each lot is tested for ca, ts, and att phenotypes and is also tested extensively by in vitro and in vivo methods to detect adventitious agents. Monovalent bulks from the three strains are subsequently blended and diluted as required to attain the desired potency with stabilizing buffers to produce the trivalent bulk vaccine. The bulk vaccine is then filled directly into individual sprayers for nasal administration (FDA: Flumist).
  • Immunization Route: Nasal spray
  • Storage: FluMist is supplied for intranasal delivery in a package of 10 pre-filled, single-use sprayers. It should be stored in a refrigerator between 2-8°C (35-46°F).
  • Approved Age for Licensed Use: Ages 2-49(FluMist website)
  • Contraindication: FLUMIST should not be administered to anyone with a known history of hypersensitivity, especially anaphylactic reactions, to eggs, egg proteins, gentamicin, gelatin, or arginine or with life-threatening reactions to previous influenza vaccinations. FLUMIST also is contraindicated in children and adolescents (2-17 years of age) receiving aspirin therapy or aspirin-containing therapy, because of the association of Reye’s syndrome with aspirin and wild-type influenza infection (FDA: Flumist).

    FLUMIST should also not be administered to anyone with asthma. FLUMIST should not be given to children who use a bronchodilator or steroids.
  • Description: This vaccine should be used for the active immunization of individuals 2-49 years of age against influenza disease.
  • Product Name: Influenza Virus Vaccine
  • Tradename: Fluvirin
  • Manufacturer: Novartis Vaccines and Diagnostics Limited
  • Vaccine Ontology ID: VO_0000046
  • CDC CVX code: 141, 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1750)
  • Host Species for Licensed Use: Human
  • Antigen: Influenza virus subtypes A and type B
  • Preparation: FLUVIRIN is a trivalent, sub-unit influenza virus vaccine prepared from virus propagated in hens’ eggs inoculated with a specific type of influenza virus suspension containing neomycin and polymyxin. Each of the influenza virus strains is harvested and clarified by filtration prior to inactivation. The inactivated virus is concentrated and purified by zonal centrifugation. Shake the syringe vigorously before administering the vaccine and shake the multidose vial preparation each time before withdrawing a dose of vaccine (FDA: Fluvirin).
  • Storage: Recommended storage conditions are between 2º and 8ºC (36º and 46ºF). Do not freeze.
  • Approved Age for Licensed Use: Persons 4 years of age and older (FDA: Fluvirin).
  • Contraindication: FLUVIRIN should not be administered to anyone under 4 years of age or to anyone with a known history of systemic hypersensitivity reactions to egg proteins, or any other component of FLUVIRIN, or life-threatening reactions to previous influenza vaccinations.
  • Product Name: Influenza Virus Vaccine
  • Tradename: Fluzone
  • Manufacturer: Sanofi Pasteur, Inc.
  • Vaccine Ontology ID: VO_0000047
  • CDC CVX code: 141, 140
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1725)
  • Host Species for Licensed Use: Human
  • Antigen: Influenza virus subtypes A and type B
  • Preservative: None
  • Allergen: Eggs
  • Preparation: Fluzone vaccine (Influenza Virus Vaccine) is prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether, (Triton X-100) producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.
    Ref: http://www.fda.gov/cber/label/fluzoneLB.pdf
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Most adverse events in clinical trials were mild and self-limited.
  • Storage: Store between 2º and 8ºC (36º and 46ºF). Do not freeze.
  • Approved Age for Licensed Use: Ages 6 months and older. (FDA: Fluzone)
  • Contraindication: FLUZONE should not be administered to anyone with known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. Allergic reactions include hives, angioedema, allergic asthma, and systemic anaphylaxis (FDA: Fluzone).
  • Description: Fluzone is a vaccine indicated for active immunization in persons 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
  • Product Name: Influenza Virus Vaccine
  • Tradename: Fluzone High-Dose
  • Manufacturer: Sanofi Pasteur
  • Vaccine Ontology ID: VO_0001127
  • CDC CVX code: 135
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Preservative: Thimerosol
  • Allergen: Eggs
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: Refrigerated at 2° to 8°C (35° to 46°F). Do not freeze.
  • Approved Age for Licensed Use: 65 years and older
  • Contraindication: Egg allergies
  • Description: Fluzone High-Dose is an inactivated influenza virus vaccine indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine (FDA: Fluzone).
  • Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
  • Manufacturer: Novartis Vaccines and Diagnostics Limited
  • Vaccine Ontology ID: VO_0000081
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Antigen: pandemic (H1N1) 2009 influenza virus
  • Preparation: Influenza A (H1N1) 2009 Monovalent Vaccine is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs which have been inoculated with a influenza virus suspension containing neomycin and polymyxin. The virus is then harvested by centrifugation and filtration and then inactivated with betapropiolactone. The surface antigens, hemagglutinin and neuraminidase are obtained from the virus particle via further centrifugation in the presence of nonylphenol ethoxylate, a process which removes most of the internal proteins. The nonylphenol ethoxylate is removed from the surface antigen preparation (FDA: H1N1 Novartis Vaccine).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Inactivated
  • Storage: Store between 2º and 8ºC (36º and 46ºF)
  • Approved Age for Licensed Use: Ages 4 and older
  • Contraindication: Hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or life-threatening reaction to previous influenza vaccination.
  • Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
  • Manufacturer: Sanofi Pasteur
  • Vaccine Ontology ID: VO_0000160
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Location Licensed: USA
  • Host Species for Licensed Use: Human
  • Antigen: 2009 Pandemic H1N1 Influenza Virus
  • Preparation: Prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is then concentrated and purified in a linear sucrose density gradient solution. The processed virus is chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution (FDA: H1N1 Vaccine Sanofi Pasteur).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: Inactivated
  • Storage: store at 2−8°C (36−46°F)
  • Approved Age for Licensed Use: Persons aged 6 months and older.
  • Contraindication: Severe hypersensitivity to egg proteins and any component of the vaccine, or life-threatening reactions after previous administration of any influenza vaccine (FDA: H1N1 Vaccine Sanofi Pasteur).
  • Vaccine Ontology ID: VO_0004311
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Human
  • HA gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector VRC-9123 expressed HA (Ledgerwood et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector: VRC-9123 prime, MIV boost (Ledgerwood et al., 2011)
  • Immunization Route: Intramuscular injection (i.m.)
  • Product Name: Influenza Virus Vaccine, H5N1
  • Tradename: Influenza Virus Vaccine, H5N1
  • Manufacturer: Sanofi Pasteur Inc.
  • Vaccine Ontology ID: VO_0000065
  • Type: Inactivated or "killed" monovalent vaccine
  • Status: Licensed
  • Location Licensed: USA (License #1725)
  • Host Species for Licensed Use: Human
  • Antigen: inactivated monovalent influenza virus H5N1
  • Preparation: A sterile suspension of H5N1 is prepared from an influenza virus propagated in embryonated chicken eggs which are harvested and inactivated with formaldehyde. The influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is "split" and then further purified and suspended in sodium phosphate-buffered isotonic sodium chloride solution (FDA: Sanofi Pasteur H5N1).
  • Immunization Route: Intramuscular injection (i.m.)
  • Virulence: There were no adverse effects recorded in clinical trials of this vaccine.
  • Storage: The H5N1 multi-dose vial should be stored at a temperature of 35 to 46 degrees Fahrenheit. DO NOT FREEZE. The vaccine should be shaken vigorously each time before withdrawning of a dose.
  • Approved Age for Licensed Use: Ages 18-64
  • Contraindication: H5N1 should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to chicken proteins, or to any component of H5N1 or who has had a life-threatening reaction to previous administration of any influenza vaccine.
  • Description: Influenza Virus Vaccine, H5N1, is an inactivated monovalent influenza virus vaccine, indicated for active immunization of persons 18 through 64 years of age at increased risk of exposure to the H5N1 influenza virus subtype.
Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Human Response

  • Vaccination Protocol: Participants were immunized on day 0 with the 2008–2009 trivalent influenza vaccine. (Bucasas et al., 2011)
  • Immune Response: Identified expression changes in 4740 transcripts. (Bucasas et al., 2011)
  • Host ADA response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of ADA in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ASH1L response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of ASHL1 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CASP1 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of CASP1 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCND3 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of CCND3 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CYLD response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of CYLD in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DDX21 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of DDX21 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DDX41 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of DDX41 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host E2F2 response
    • Description: 2008-2009 trivalent vaccine induced downregulation of E2F2 in PBMC's on day 3 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host E2F2 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of E2F2 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host E2F2 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of E2F2 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ERCC1 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of ERCC1 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EXOSC3 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of EXOSC3 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EXOSC3 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of EXOSC3 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FCER1G response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of FCER1G in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HNRNPU response
    • Description: 2008-2009 trivalent vaccine induced upregulation of HNRNPU in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL2 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of IL2 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of IL-6 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JAK2 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of JAK2 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LYN response
    • Description: 2008-2009 trivalent vaccine induced upregulation of LYN in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MYD88 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of MYD88 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NFKBIA response
    • Description: 2008-2009 trivalent vaccine induced upregulation of NFKBIA in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OASL response
    • Description: 2008-2009 trivalent vaccine induced upregulation of OASL in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POLR3E response
    • Description: 2008-2009 trivalent vaccine induced upregulation of POLR3E in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PQBP1 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of PQBP1 in PBMC's on day 14 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RIPK2 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of RIPK2 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host S100A4 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of S100A4 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLFN11 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of SLFN11 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STAT1 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of STAT1 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STAT4 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of STAT4 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR7 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of TLR7 in PBMC's on day 1(Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of TLR8 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRAF3IP3 response
    • Description: 2008-2009 trivalent vaccine induced upregulation of TRAF3IP3 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host USP14 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of USP14 in PBMC's on day 1 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF112 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of ZNF112 in PBMC's on day 14 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF224 response
    • Description: 2008–2009 trivalent influenza vaccine induced upregulation of ZNF224 in PBMC's on day 14 (Bucasas et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Volunteer recruitment and vaccination protocols for this study were approved by the Vanderbilt Institutional Review Board (IRB#111030 “CLR-03 2011-Immune Cells and Soluble Factors from Healthy Donor”). After obtaining written informed consent, thirty one subjects were enrolled in this study. Twenty-nine subjects provided 90mL blood samples to develop our phenotyping and cell sorting protocols and to establish baseline blood profiling information; for these purposes, twenty three subjects provided a single blood sample, and six subjects provided four samples over subsequent days on the same schedule as proposed for vaccinated subjects. Once the cell sorting pipeline was in place, two subjects were vaccinated with a single dose of 2011–2012 seasonal trivalent inactivated influenza vaccine (TIV) (strains included: A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). Blood samples (90mL) from the two vaccinated subjects were processed prior to vaccination (day 0) and at days 1, 3, and 7 post-vaccination for downstream RNA-seq and quantitative proteomics analysis. (Hoek et al., 2015)
  • Host CXCR3 response
    • Description: CXCR3, the receptor for CXCL10/IP-10, was significantly up-regulated in both PBMC and sorted B cell samples after TIV vaccination(Hoek et al., 2015).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: The 2011-2012 TIV vaccine induced upregulation of TNFRSF17 in sorted B cell samples from both subjects 7 days after vaccination (Hoek et al., 2015).
    • Detailed Gene Information: Click Here.
  • Host XBP1 response
    • Description: The 2011-2012 TIV vaccine induced upregulation of XBP1 in sorted B cell samples from both subjects 7 days after vaccination
    • Detailed Gene Information: Click Here.

Human Response

  • Host Strain: healthy human subjects in USA
  • Vaccination Protocol: A randomized, double-blinded, placebo-controlled, multicenter study in healthy subjects ages 18 to less than 65 years in the United States. Subjects received AFLURIA in either a single-dose or multi-dose formulation.
  • Immune Response: The single-dose and multi-dose formulations elicited similar immune responses.
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: The most common local side-effects were tenderness, pain, redness and swelling of the injection site. Common systemic reactions included: headache, malaise, and muscle aches. Severe allergic reactions such as anaphylactic shock have been observed in individuals vaccinated with AFLURIA.

Human Response

  • Vaccination Protocol: A randomized, controlled study that enrolled 275 healthy subjects ages 65 years and older in the United Kingdom. This study compared AFLURIA® with a European-licensed trivalent inactivated influenza vaccine as an active control (FDA: Afluria).
  • Immune Response: The post-hoc analysis of serum HI antibody responses showed that the lower bound of the 95% confidence internals (CI) for subjects with HI antibody titers of 1:40 or greater after vaccination exceeds 70% for each of the three strains (H1N, H3N2, and B) in the vaccine. In human subjects aged more than 65 years, significant serum hemagglutination-inhibiting (HI) antibody responses to AFLURIA were induced for all three virus strains (HiNi, H3N2, and B), but the level of the HI antibody response appeared lower than the similar study conducted in the ages 18 to less than 65 years (FDA: Afluria).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: The recorded side effects of the vaccination were similar to those observed in the United States study regarding AFLURIA.

Human Response

  • Vaccination Protocol: A randomized, controlled study that enrolled 406 healthy subjects ages 18 years and older in the United Kingdom (FDA: Afluria).
  • Immune Response: The post-hoc analysis of serum HI antibody responses showed that the lower bound of the 95% confidence internals (CI) for subjects with HI antibody titers of 1:40 or greater after vaccination exceeds 70% for each of the three strains (H1N, H3N2, and B) in the vaccine (FDA: Afluria).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Side Effects were similar to those observed in the two previous clinical trials in the United States and the United Kingdom.

Human Response

  • Vaccination Protocol: Study in Argentina of 632 adults ranging from ages 18-64, subjects were given Agriflu or comparator vaccine. 424 subjects received Agriflu and 219 received the comparator vaccine (FDA: Agriflu).
  • Immune Response: Serum HI antibody responses 21 days after vaccination with AGRIFLU met the pre-specified co-primary endpoint criteria for all three viral strains included in the vaccine.
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: Study done in the Dominican Republic of 1507 adults ages 18-49. Subjects were randomly assigned at a 2:2:2:1 ratio to receive either one of three consecutive AGRIFLU lots or the US-licensed influenza vaccine used for comparison (FDA: Agriflu).
  • Immune Response: Serum HI antibody responses 21 days after vaccination with AGRIFLU met the pre-specified co-primary endpoint criteria for all three viral strains included in the vaccine.
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: A randomized, double-blind, placebo-controlled study was conducted in healthy subjects 18 to 64 years of age in the United States. After administration of FLUARIX (n = 745), the immune responses to each of the antigens contained in FLUARIX were evaluated in sera obtained 21 days and were compared to those following administration of a placebo vaccine (n = 190).
  • Immune Response: FLUARIX induced strong antibody response with significant hemagglutination inhibition.
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Adverse effects include varied levels of pain in the injection site, redness, swelling, muscle aches, fatigue, and headache. Immediate, presumably allergic, reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination (GSK: US Fluarix).

Human Response

  • Vaccination Protocol: A randomized, single-blind, active-controlled US study, immunological non-inferiority of FLUARIX (N = 923) was compared with FLUZONE (N = 922), a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA). Subjects 18 to 64 years and ≥65 years of age were evaluated for immune responses to each of the vaccine antigens 21 days following vaccination (FDA: Fluarix).
  • Immune Response: FLUARIX was non-inferior to the comparator influenza vaccine based on antibody geometric mean titers (GMTs) of serum HI antibodies and the percentage of subjects who achieved seroconversion, defined as at least a 4-fold increase in serum HI titer over baseline to ≥1:40, following vaccination (FDA: Fluarix).
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: The immune response of FLUARIX was compared to FLUZONE, a US-licensed trivalent, inactivated influenza virus vaccine (Sanofi Pasteur SA), in a single-blind, randomized study in a subset of children 6 months to <5 years of age (FDA: Fluarix).
  • Immune Response: Non-inferiority of the immune response for FLUARIX to comparator influenza vaccine for subjects 6 months to <5 years of age was not demonstrated mainly due to lower antibody response to FLUARIX compared to the comparator influenza vaccine in subjects 6 months to <3 years of age. In subjects 3 years to <5 years of age, FLUARIX met at least one of the pre-specified criteria for demonstration of non-inferiority (GMT and seroconversion rate) for the influenza A strains but not for the influenza B strain (FDA: Fluarix).

Human Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Host ACADM response
    • Description: Compared to Day 0, ACADM was UP regulated in PMBCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host AKR1C3 response
    • Description: Compared to Day 0, AKR1C3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ATF6B response
    • Description: The expression of ATF6B, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CAV1 response
    • Description: Compared to Day 0, CAV1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD38 response
    • Description: Compared to Day 0, CD38, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSP90B1 response
    • Description: The expression of HSP90B1, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HYOU1 response
    • Description: Compared to Day 0, HYOU1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFNGR2 response
    • Description: Compared to Day 0, IFNGR2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHA1 response
    • Description: Compared to Day 0, IGHA1, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHM response
    • Description: Compared to Day 0, IGHM, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKC response
    • Description: Compared to Day 0, IGKC, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGL@ response
    • Description: Compared to Day 0, IGL@, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL10RB response
    • Description: Compared to Day 0, IL10RB was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KDELR2 response
    • Description: Compared to Day 0, KDELR2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MANF response
    • Description: The expression of MANF, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MOGS response
    • Description: Compared to Day 0, MOGS was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA4 from humans response
    • Description: he expression of PDIA4, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA6 response
    • Description: Compared to Day 0, PDIA6 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA6 response
    • Description: Compared to Day 0, PDIA6 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PECAM1 response
    • Description: The expression of PECAM1, which is associated with ASC (adipose stromal) cell differentiation, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2AF1 response
    • Description: The expression of POU2AF1, which is associated with the unfolded protein response, at Day 3 and 7 after vaccination with Fluarix was positively correlated with the baseline-normalized HAI antibody response at day 28 post-vaccination (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2F2 response
    • Description: Compared to Day 0, POU2F2, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPN1 response
    • Description: Compared to Day 0, RPN1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPN2 response
    • Description: Compared to Day 0, RPN2 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC11C response
    • Description: Compared to Day 0, SEC 11C was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC23B from humans response
    • Description: Compared to Day 0, SEC 23B was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC24D response
    • Description: Compared to Day 0, SEC 24D was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPCS2 response
    • Description: Compared to Day 0, SPCS2 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SRPR response
    • Description: Compared to Day 0, SRPR was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SSR1 response
    • Description: Compared to Day 0, SSR1 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TCF7L2 response
    • Description: Compared to Day 0, TCFL7L2 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR5 from humans response
    • Description: Compared to Day 0, TLR5 was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: Compared to Day 0, TNFRSF17, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF13 response
    • Description: Compared to Day 0, TNFSF13, which is associated with ASC (adipose stromal) cell differentiation, was positively correlated with the HAI antibody response at Day 3 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TXNDC5 response
    • Description: Compared to Day 0, TXNDC5 was positively correlated with the HAI antibody response at Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011). The following host responses are UP regulated gene expressions which experienced at least .33 fold increase in expression.
  • Host AKR1C3 response
    • Description: Compared to Day 0, AKR1C3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host APOBEC3B response
    • Description: Compared to Day 0, [APOBEC3B] was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host APOBEC3F response
    • Description: Compared to Day 0, APOBEC3F was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host ARF1 response
    • Description: Compared to Day 0, ARF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host ARFIP1 response
    • Description: Compared to Day 0, ARF1P1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host C14orf119 response
    • Description: Compared to Day 0, C14orf119 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C19orf10 response
    • Description: Compared to Day 0, C19orf10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C3AR1 response
    • Description: Compared to Day 0, C3AR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CASP1 response
    • Description: Compared to Day 0, CASP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCDC56 response
    • Description: Compared to Day 0, CCDC56 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCR2 response
    • Description: Compared to Day 0, CCR2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD27 response
    • Description: Compared to Day 0, CD27 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD300A response
    • Description: Compared to Day 0, CD300A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD38 response
    • Description: Compared to Day 0, CD38 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CDKN1C response
    • Description: Compared to Day 0, CDKN1C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host COPB2 response
    • Description: Compared to Day 0, COPB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CTBP2 response
    • Description: Compared to Day 0, CTBP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CTSC response
    • Description: Compared to Day 0, CTSC was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CX3CR1 response
    • Description: Compared to Day 0, CX3CR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CYAT1 response
    • Description: Compared to Day 0, CYAT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EAF2 response
    • Description: Compared to Day 0, EAF2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ECHDC1 response
    • Description: Compared to Day 0, ECHDC1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ERLEC1 response
    • Description: Compared to Day 0, [ERLEC1] was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FAM26F response
    • Description: Compared to Day 0, FAM26F was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FKBP11 response
    • Description: Compared to Day 0, FKBP11 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GAPT response
    • Description: Compared to Day 0, GAPT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GGH response
    • Description: Compared to Day 0, GGH was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP4 response
    • Description: Compared to Day 0, GIMAP4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP8 response
    • Description: Compared to Day 0, GIMAP8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GPBAR1 response
    • Description: Compared to Day 0, GPBAR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GTF2H1 response
    • Description: Compared to Day 0, GTF2H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSP90B1 response
    • Description: Compared to Day 0, HSP90B1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IDH1 response
    • Description: Compared to Day 0, IDH1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHD response
    • Description: Compared to Day 0, IGHD was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHG1 response
    • Description: Compared to Day 0, IGHG1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGHM response
    • Description: Compared to Day 0, IGHM was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGJ response
    • Description: Compared to Day 0, IGJ was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKC response
    • Description: Compared to Day 0, IGKC was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGKV3-20 response
    • Description: Compared to Day 0, IGKV3-20 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLL1 response
    • Description: Compared to Day 0, IGLL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV1-44 response
    • Description: Compared to Day 0, IGLV1-44 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV2-23 response
    • Description: Compared to Day 0, IGLV2-23 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IGLV3-19 response
    • Description: Compared to Day 0, IGLV3-19 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ITM2C response
    • Description: Compared to Day 0, ITM2C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KCNE3 response
    • Description: Compared to Day 0, KCNE3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLHL14 response
    • Description: Compared to Day 0, KLHL14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLRD1 response
    • Description: Compared to Day 0, KLRD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LAIR1 response
    • Description: Compared to Day 0, LAIR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LFNG response
    • Description: Compared to Day 0, LFNG was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100130100 response
    • Description: Compared to Day 0, LOC100130100 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100287723 response
    • Description: Compared to Day 0, LOC100287723 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC284837 response
    • Description: Compared to Day 0, LOC284837 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC91316 response
    • Description: Compared to Day 0, LOC91316 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC96610 response
    • Description: Compared to Day 0, LOC96610 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LYST response
    • Description: Compared to Day 0, LYST was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAN1A1 response
    • Description: Compared to Day 0, MAN1A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MANF response
    • Description: Compared to Day 0, MANF was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MGAT2 response
    • Description: Compared to Day 0, MGAT2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MOSPD2 response
    • Description: Compared to Day 0, MOSPD2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A4A response
    • Description: Compared to Day 0, MS4A4A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A7 response
    • Description: Compared to Day 0, MS4A7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NDUFA8 response
    • Description: Compared to Day 0, NDUFA8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OSTM1 response
    • Description: Compared to Day 0, OSTM1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PCMT1 response
    • Description: Compared to Day 0, PCMT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PDIA5 response
    • Description: Compared to Day 0, PDIA5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PMS2P2 response
    • Description: Compared to Day 0, PMS2P2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POU2AF1 response
    • Description: Compared to Day 0, POU2AF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PPAPDC1B response
    • Description: Compared to Day 0, PPAPDC1B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PRDX4 response
    • Description: Compared to Day 0, PRDX4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PRF1 response
    • Description: Compared to Day 0, PRF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAB10 response
    • Description: Compared to Day 0, RAB10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAB8A response
    • Description: Compared to Day 0, RAB8A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAP2A response
    • Description: Compared to Day 0, RAP2A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNASE2 response
    • Description: Compared to Day 0, RNASE2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RPS27 response
    • Description: Compared to Day 0, RPS27 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RRM2 response
    • Description: Compared to Day 0, RRM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC11C response
    • Description: Compared to Day 0, SEC 11C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC24A response
    • Description: Compared to Day 0, SEC 24A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEC61A1 response
    • Description: Compared to Day 0, SEC1A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SEL1L3 response
    • Description: Compared to Day 0, SEL1L3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SH2D1B response
    • Description: Compared to Day 0, SH2D1B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF6 response
    • Description: Compared to Day 0, SLAMF6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF7 response
    • Description: Compared to Day 0, SLAMF7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLC44A1 response
    • Description: Compared to Day 0, SLC44A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SNORA28 response
    • Description: Compared to Day 0, SNORA28 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPTLC2 response
    • Description: Compared to Day 0, SPTLC2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SSR3 response
    • Description: Compared to Day 0, SSR3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STT3A response
    • Description: Compared to Day 0, STT3A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SUV420H1 response
    • Description: Compared to Day 0, SUV420H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR5 from humans response
    • Description: Compared to Day 0, TLR5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: Compared to Day 0, TLR8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFAIP8L2 response
    • Description: Compared to Day 0, TNFAIP8L2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: Compared to Day 0, TNFRSF17 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNIP1 response
    • Description: Compared to Day 0, TNIP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TPD52 response
    • Description: Compared to Day 0, TPD52 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRAM2 response
    • Description: Compared to Day 0, TRAM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRIM69 response
    • Description: Compared to Day 0, TRIM69 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TXNDC5 response
    • Description: Compared to Day 0, TXNDC5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TYMS response
    • Description: Compared to Day 0, TYMS was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VPS35 response
    • Description: Compared to Day 0, VPS35 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZEB2 response
    • Description: Compared to Day 0, ZEB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZKSCAN1 response
    • Description: Compared to Day 0, ZKSCAN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF146 response
    • Description: Compared to Day 0, ZNF146 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF207 response
    • Description: Compared to Day 0, ZNF207 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF573 response
    • Description: Compared to Day 0, ZNF573 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZWINT response
    • Description: Compared to Day 0, ZWINT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Fluarix (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: A randomized controlled clinical trial including 1,000 subjects with ages 18 -65 years in the United States. These subjects were randomized to receive FLULAVAL or a US-licensed trivalent, inactivated influenza virus vaccine (FLUZONE) .
  • Immune Response: The analysis of the following co-primary endpoints was performed for each HA antigen contained in the vaccine: 1) assessment of the lower bounds of 2-sided 95% confidence intervals for the proportion of subjects with HI antibody titers of ≥1:40 after vaccination, and 2) assessment of the lower bounds of 2-sided 95% confidence intervals for rates of seroconversion (defined as a 4-fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥1:10, or an increase in titer from <1:10 to ≥1:40) (FDA: FluLaval).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: The most common local and systemic adverse events were pain, redness, and/or swelling at the injection site, headache, fatigue, myalgia, low grade fever, and malaise.

Human Response

  • Vaccination Protocol: A randomized, blinded, and controlled clinical trial was conducted in Canada and included a sample population of 658 adults ages 50years and older. This study compared four vaccine groups: FLULAVAL, a similar investigational formulation of FLULAVAL with reduced thimerosal, and 2 Canadian-licensed trivalent influenza vaccines (FDA: FluLaval).
  • Immune Response: The serum Hemagglutination-Inhibitng (HI) antibody responses to FLULAVAL met the pre-specified seroconversion criteria for all 3 virus strains (A/Brisbane/59/2007 (H1N1)-like virus (A/Brisbane/59/2007 IVR-148), A/Brisbane/10/2007 (H3N2)-like virus (A/Uruguay/716/2007 NYMC X-175C), and B/Florida/4/2006-like virus (B/Florida/4/2006)), and also the pre-specified criterion for the proportion of subjects with HI titers ≥1:40 for both influenza A viruses. In both trials, both FLULAVAL and the comparator vaccine did not meet the pre-specified criterion for the proportion of subjects with HI titers ≥1:40 for the influenza B virus (FDA: FluLaval).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: The most common local adverse effects included: pain, redness and swelling. The most common systemic adverse effects were headache, fatigue and myalgia. Due to the trial featuring a sample ages 50 years and older, there was a longer safety follow-up that helped to show more spontaneous adverse event reports as compared to the United States trial.

Human Response

  • Vaccination Protocol: A multinational, randomized, double-blind, active-controlled trial (MI-CP111) was performed to assess the efficacy and safety of FLUMIST compared to an injectable influenza vaccine in children <5 years of age, using the refrigerated formulation.
  • Side Effects: Side effects found in children included: fever, cough, sore throat, or runny nose/nasal congestion.
  • Efficacy: In the primary efficacy analysis, FLUMIST demonstrated a 44.5% (95% CI: 22.4, 60.6) reduction in influenza rate compared to active control as measured by culture-confirmed modified CDC-ILI caused by wild-type strains antigenically similar to those contained in the vaccine (FDA: Flumist).

Human Response

  • Immune Response: FluMist is not indicated in children <24 months of age. In a clinical trial, among children 6-23 months of age, wheezing requiring bronchodilator therapy or with significant respiratory symptoms occurred in 5.9% of FluMist recipients compared to 3.8% of active control (injectable influenza vaccine made by Sanofi Pasteur Inc.) recipients (Relative Risk 1.5, 95% CI: 1.2, 2.1). Wheezing was not increased in children ≥24 months of age. (FDA: Flumist)
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Side effects found in children included: fever, cough, sore throat, or runny nose/nasal congestion
  • Efficacy: A randomized, double-blind, placebo-controlled trial (D153-P501) was performed to evaluate the efficacy of FLUMIST in children 12 to 35 months of age using the refrigerated formulation (FDA: Flumist).

Human Response

  • Vaccination Protocol: AV006 was a multi-center, randomized, double-blind, placebo-controlled trial performed in U.S. children without high-risk medical conditions to evaluate the efficacy of FLUMIST against culture-confirmed influenza over two successive seasons using the frozen formulation (FDA: Flumist).
  • Side Effects: Side effects found in children included: fever, cough, sore throat, or runny nose/nasal congestion
  • Efficacy: FLUMIST demonstrated 87.0% efficacy against culture-confirmed influenza illness (FDA: Flumist).

Human Response

  • Vaccination Protocol: AV009 was a multi-center, randomized, double-blind, placebo-controlled trial of FLUMIST to evaluate effectiveness in adults 18-64 years of age without high-risk medical conditions.
  • Side Effects: Side effects of this study include: runny nose, headache, sore throat, tiredness/weakness, muscle aches, cough, and chills

Human Response

  • Vaccination Protocol: In this study the safety and shedding of vaccine virus following FLUMIST administration was evaluated in 57 HIV-infected and 54 HIV-negative adults 18-58 years of age. The study was a randomized, double-blind, placebo controlled trial using the frozen formulation
  • Side Effects: No serious adverse events were reported during the one-month follow-up period and no adverse effects on HIV viral load or CD4 counts were identified following FLUMIST administration (FDA: Flumist).
  • Description: The effectiveness of FLUMIST in preventing influenza illness in HIV-infected individuals has not been evaluated

Human Response

  • Vaccination Protocol: A single open-label dose of trivalent LAIV was administered intranasally to 344 subjects in 3 age cohorts: 5–8, 9–17, and 18–49 years of age. Shedding was determined by culture of nasal swabs (on days 1–7, daily; days 9–25, every other day; and day 28). Immunogenicity was measured as serum strain-specific hemagglutinin inhibition (HAI) titers (days 0, 28) (Block et al., 2008).
  • Immune Response: Among subjects aged 5–8 years, 9–17 years, and 18–49 years, 44%, 27%, and 17% of subjects, respectively, shed vaccine virus after vaccination. Shedding incidence was inversely correlated to age and baseline serum HAI antibody titer. The seroresponse rate (4-fold rise in HAI antibody titers) to at least one strain was 59% (68%, 64%, and 47%, respectively, by age group). Strain-specific rates were higher in baseline seronegative and serosusceptible subjects (Block et al., 2008).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Reactogenicity, most commonly runny nose, headache, and sore throat, was not associated with shedding or seroresponse (Block et al., 2008).

Human Response

  • Vaccination Protocol: FluMist was used to vaccinate human subjects. Peripheral blood mononuclear cells (PBMCs) were collected from all 56 vaccinees on days 0, 3, and 7 after vaccination. Microarray experiment was then performed using the PBMC samples.
  • Vaccine Immune Response Type: VO_0000286
  • Host APOBEC3G response
    • Description: APOBEC3G, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C3AR1 response
    • Description: C3AR1, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CASP1 response
    • Description: CASP1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD14 response
    • Description: CD14, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD244 response
    • Description: CD244, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 but not on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CIITA response
    • Description: CIITA, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CSF1R from humans response
    • Description: CSF1R, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CXCL1 response
    • Description: CXCL1, a gene closely associated with interferon signal pathways, was down-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host EIF2S1 response
    • Description: EIF2S1, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host human STAT1 response
    • Description: STAT1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ICAM1 response
    • Description: ICAM1, a gene closely associated with interferon signal pathways, was down-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ICAM2 response
    • Description: ICAM2, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFI16 response
    • Description: IFI16, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFI35 response
    • Description: IFI35, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6R response
    • Description: IL6R, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 but not on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL8 response
    • Description: IL8, a gene closely associated with interferon signal pathways, was down-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRAK3 response
    • Description: IRAK3, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRF5 response
    • Description: IRF5, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JUN response
    • Description: JUN, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 but not on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAVS response
    • Description: MAVS, a gene closely associated with interferon signal pathways, was up-regulated on Day 7 but not on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MX1 response
    • Description: MX1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MX2 response
    • Description: MX2, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS1 response
    • Description: OAS1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS1 response
    • Description: OAS1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS2 response
    • Description: OAS2, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS3 response
    • Description: OAS3, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OSM response
    • Description: OSM, a gene closely associated with interferon signal pathways, was down-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PLSCR1 response
    • Description: PLSCR1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SOCS3 response
    • Description: SOCS3, a gene closely associated with interferon signal pathways, was down-regulated on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STAT2 response
    • Description: STAT2, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TICAM2 response
    • Description: TICAM2, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR7 response
    • Description: TLR7, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: TLR8, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF10 response
    • Description: TNFSF10, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF13 response
    • Description: TNFSF13, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF13B response
    • Description: TNFSF13B, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 but not on Day 7 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host XAF1 response
    • Description: XAF1, a gene closely associated with interferon signal pathways, was up-regulated on Day 3 after FluMist vaccination. The expression of this gene was not altered by the vaccination of trivalent inactivated influenza vaccine (TIV) (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: FluMist was used to vaccinate human subjects. Peripheral blood mononuclear cells (PBMCs) were collected from all 56 vaccinees on days 0 (basic line) and 7 after vaccination. The PBMCs were used to sort out specific cell types, including myeloid dendritic cells (mDCs), plasmacytoid dendritic cells (pDCs), monocytes, and B cells. Microarray experiments were then performed using the samples of whole PBMCs and specific cell types (Nakaya et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Host ABCB1 response
    • Description: Compared to Day 0 (baseline), ABCB1 was up-regulated in pDCs and B-cells post vaccination with FluMist. No change in ABCB1 expression was observed in PMBCs, mononcytes, or mDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host ALCAM response
    • Description: Compared to Day 0 (baseline), ALCAM was up-regulated in pDCs post vaccination with FluMist. No change in ALCAM expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ANXA2 response
    • Description: Compared to Day 0 (base line), ANXA2 was up-regulated in PMBCs and pDCs at Day 7 post vaccination with FluMist. No change in ANXA2 expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host APOBEC3F response
    • Description: Compared to Day 0 (base line), APOBEC3F was up-regulated in PMBCs but was down-regulated in the mDCs at Day 7 post vaccination with FluMist. No change in APOBEC3F expression was observed in monocytes, pDCs, or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host APOBEC3G response
    • Description: Compared to Day 0 (base line), APOBEC3G was up-regulated in PMBCs and pDCs at Day 7 post vaccination with FluMist. No change in APOBEC3G expression was observed in monocytes, mDCs, or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C1QBP response
    • Description: Compared to Day 0 (baseline), C1QBP was up-regulated in pDCs post vaccination with FluMist. No change in C1QBP expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C5AR1 response
    • Description: Compared to Day 0 (baseline), C5AR1 was down-regulated in PMBCs but up-regulated in monocytes at Day 7 post vaccination with FluMist. No change in C5AR1 expression was observed in mDCs, pDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCL3 response
    • Description: Compared to Day 0 (baseline), CCL3 was up-regulated in monocytes post vaccination with FluMist. No change in CCL3 expression was observed in PMBCs, monocytes, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCL4 response
    • Description: Compared to Day 0 (baseline), CCL4 was up-regulated in monocytes post vaccination with FluMist. No change in CCL4 expression was observed in PMBCs, monocytes, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCND3 response
    • Description: Compared to Day 0 (baseline), CCND3 was up-regulated in monocytes, mDCs, pDCs, and B-cells post vaccination with FluMist. No change in CCND3 expression was observed in PMBCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCND3 response
    • Description: Compared to Day 0 (baseline), CCND3 was up-regulated in monocytes, mDCs, pDCs, and B-cells post vaccination with FluMist. No change in CCND3 expression was observed in PMBCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCND3 response
    • Description: Compared to Day 0 (baseline), CCND3 was up-regulated in monocytes, mDCs, pDCs, and B-cells post vaccination with FluMist. No change in CCND3 expression was observed in PMBCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCR1 response
    • Description: Compared to Day 0 (baseline), CCR1 was up-regulated in pDCs post vaccination with FluMist. No change in CCR1 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCR2 response
    • Description: Compared to Day 0 (baseline), CCR2 was up-regulated in PMBCs, monocytes and pDCs post vaccination with FluMist. No change in CCR2 expression was observed in mDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD55 response
    • Description: Compared to Day 0 (baseline), CD55 was down-regulated in PMBCs but up-regulated in pDCs at Day 7 post vaccination with FluMist. No change in CD55 expression was observed in monocytes, mDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD86 response
    • Description: Compared to Day 0 (baseline), CD86 was up-regulated in PMBCs and monocytes post vaccination with FluMist. No change in CD86 expression was observed in mDCs, pDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CIITA response
    • Description: Compared to Day 0 (base line), CIITA was up-regulated in PMBCs and monocytes post vaccination with FluMist. No change in CIITA expression was observed in mDCs or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CRK response
    • Description: Compared to Day 0 (baseline), CRK was up-regulated in mDCs post vaccination with FluMist. No change in CRK expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CSF2RA response
    • Description: Compared to Day 0 (baseline), CSF2RA was up-regulated in PMBCs, mDCs, and pDCs post vaccination with FluMist. No change in CSF2RA expression was observed in B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CSF3 response
    • Description: Compared to Day 0 (baseline), CSF3 was down-regulated in pDCs post vaccination with FluMist. No change in CSF3 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CX3CR1 response
    • Description: Compared to Day 0 (base line), CX3CR1 was up-regulated in PMBCs and monocytes post vaccination with FluMist. No change in CX3CR1 expression was observed in mDCs, pDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CXCL1 response
    • Description: Compared to Day 0 (baseline), CXCL1 was down-regulated in PMBCs but up-regulated in monocytes at Day 7 post vaccination with FluMist. No change in CXCL1 expression was observed in mDCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DAPK1 response
    • Description: Compared to Day 0 (base line), DAPK1 was up-regulated in PMBCs and pDCs post vaccination with FluMist. No change in DAPK1 expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EIF2S1 response
    • Description: Compared to Day 0 (base line), EIF2S1 was up-regulated in PMBCs and pDCs at Day 7 post vaccination with FluMist. No change in EIF2S1 expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ETS2 response
    • Description: Compared to Day 0 (baseline), ETS2 was up-regulated in monocytes and mDCs post vaccination with FluMist. No change in ETS2 expression was observed in PMBCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FLT3 response
    • Description: Compared to Day 0 (base line), FLT3 was up-regulated in PMBCs and pDCs post vaccination with FluMist. No change in FLT3 expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FOS response
    • Description: Compared to Day 0 (baseline), FOS was up-regulated in mDCs post vaccination with FluMist. No change in FOS expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSPA1A response
    • Description: Compared to Day 0 (baseline), HSPA1A was up-regulated in monocytes post vaccination with FluMist. No change in HSPA1A expression was observed in PMBCs, monocytes, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSPD1 response
    • Description: Compared to Day 0 (baseline), HSPD1 was up-regulated in pDCs post vaccination with FluMist. No change in HSPD1 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host Human CAMK4 (CaMKIV) response
    • Description: Human CAMK4 is a marker of Flumist-induced protective immunity (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFNAR1 response
    • Description: Compared to Day 0 (baseline), IFNAR1 was up-regulated in mDCs post vaccination with FluMist. No change in IFNAR1 expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFNGR1 response
    • Description: Compared to Day 0 (baseline), IFNGR1 was down-regulated in PMBCs and B-cells but up-regulated in monocytes at Day 7 post vaccination with FluMist. No change in IFNGR1 expression was observed in mDCs or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFRD1 response
    • Description: Compared to Day 0 (baseline), IFRD1 was down-regulated in PMBCs but up-regulated in monocytes, mDCs, and pDCs at Day 7 post vaccination with FluMist. No change in IFRD1 expression was observed in B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IKBKB response
    • Description: Compared to Day 0 (baseline), IKBKB was up-regulated in PMBC, mDCs, and pDCs post vaccination with FluMist. No change in IKBKB expression was observed in monocytes or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL10RB response
    • Description: Compared to Day 0 (baseline), IL10RB was up-regulated in PMBCs and monocytes but was down-regulated in B-cells at Day 7 post vaccination with FluMist. No change in IL10RB expression was observed in mDCs or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL13RA1 response
    • Description: Compared to Day 0 (baseline), IL13RA1 was up-regulated in mDCs and pDCs post vaccination with FluMist. No change in IL13RA1 expression was observed in PMBCs, monocytes, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL18R1 response
    • Description: Compared to Day 0 (baseline), IL18R1 was up-regulated in mDCs post vaccination with FluMist. No change in IL18R1 expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL1B response
    • Description: Compared to Day 0 (baseline), IL1B was down-regulated in PMBCs and pDCs at Day 7 post vaccination with FluMist. No change in IL1B expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL4R response
    • Description: Compared to Day 0 (baseline), ISG20 was up-regulated in mDCs and pDCs post vaccination with FluMist. No change in ISG20 expression was observed in PMBCs, monocytes, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6 response
    • Description: Compared to Day 0 (baseline), IL6 was up-regulated in monocytes but down-regulated in pDCs post vaccination with FluMist. No change in IL6 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6R response
    • Description: Compared to Day 0 (baseline), IL6R was up-regulated in pDCs post vaccination with FluMist. No change in IL6R expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6ST response
    • Description: Compared to Day 0 (baseline), IL6ST was down-regulated in B-cells post vaccination with FluMist. No change in IL6ST expression was observed in PMBCs, monocytes, or mDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL8 response
    • Description: Compared to Day 0 (baseline), IL8 was down-regulated in PMBCs but up-regulated in monocytes at Day 7 post vaccination with FluMist. No change in IL8 expression was observed in mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRAK1 response
    • Description: Compared to Day 0 (baseline), IRAK1 was up-regulated in monocytes post vaccination with FluMist. No change in IRAK1 expression was observed in PMBCs, monocytes, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRF2 response
    • Description: Compared to Day 0 (baseline), IRF2 was up-regulated in pDCs post vaccination with FluMist. No change in IRF2 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRF7 response
    • Description: Compared to Day 0 (base line), IRF7 was down-regulated in monocytes at Day 7 post vaccination with FluMist. No change in IRF7 expression was observed in mDCs, pDCs, or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ISG20 response
    • Description: Compared to Day 0 (baseline), ISG20 was up-regulated in pDCs post vaccination with FluMist. No change in ISG20 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ITGA4 response
    • Description: Compared to Day 0 (baseline), ITGA4 was up-regulated in pDCs post vaccination with FluMist. No change in ITGA4 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IVNS1ABP response
    • Description: Compared to Day 0 (baseline), IVNS1ABP was up-regulated in mDCs post vaccination with FluMist. No change in IVNS1ABP expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JAK2 response
    • Description: Compared to Day 0 (baseline), JAK2 was up-regulated in pDCs post vaccination with FluMist. No change in JAK2 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JUN response
    • Description: Compared to Day 0 (base line), JUN was up-regulated in PMBCs, monocytes, and B-cells post vaccination with FluMist. No change in JUN expression was observed in mDCs, or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KRAS response
    • Description: Compared to Day 0 (baseline), KRAS was down-regulated in PMBCs and mDCs at Day 7 post vaccination with FluMist. No change in KRAS expression was observed in monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAP3K14 response
    • Description: Compared to Day 0 (baseline), MAP3K14 was up-regulated in monocytes post vaccination with FluMist. No change in MAP3K14 expression was observed in PMBCs, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAP3K5 response
    • Description: Compared to Day 0 (baseline), MAP3K5 was up-regulated in pDCs post vaccination with FluMist. No change in MAP3K5 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAP3K7 response
    • Description: Compared to Day 0 (baseline), MAP3K7 was up-regulated in pDCs post vaccination with FluMist. No change in MAP3K7 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAPK1 response
    • Description: Compared to Day 0 (base line), MAPK1 was up-regulated in PMBCs, mDCs, and pDCs post vaccination with FluMist. No change in MAPK1 expression was observed in monocytes or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAPK14 response
    • Description: Compared to Day 0 (baseline), MAPK14 was up-regulated in pDCs post vaccination with FluMist. No change in MAPK14 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAPKAPK2 response
    • Description: Compared to Day 0 (baseline), MAPKAPK2 was down-regulated in PMBCs and monocytes at Day 7 post vaccination with FluMist. No change in MAPKAPK2 expression was observed in mDCs, pDCs, or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MNDA response
    • Description: Compared to Day 0 (base line), MNDA was up-regulated in PMBCs and monocytes but was down-regulated in the B-cells at Day 7 post vaccination with FluMist. No change in MNDA expression was observed in mDCs or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MSR1 response
    • Description: Compared to Day 0 (baseline), MSR1 was up-regulated in mDCs post vaccination with FluMist. No change in MSR1 expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS1 response
    • Description: Compared to Day 0 (base line), OAS1 was up-regulated in PMBCs and pDCs post vaccination with FluMist. No change in OAS1 expression was observed in monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMis (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PIK3C3 response
    • Description: Compared to Day 0 (base line), PIK3C3 was down-regulated in the mDCs cells but was up-regulated in B-cells at Day 7 post vaccination with FluMist. No change in PIK3C3 expression was observed in monocytes or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PIK3CA response
    • Description: Compared to Day 0 (baseline), PIK3CA was down-regulated in PMBCs and mDCs but up-regulated in pDCs at Day 7 post vaccination with FluMist. No change in PIK3CA expression was observed in monocytes or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PIK3CG response
    • Description: Compared to Day 0 (baseline), PIK3CG was down-regulated in monocytes post vaccination with FluMist. No change in PIK3CG expression was observed in PMBCs, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PRKCA from humans response
    • Description: Compared to Day 0 (baseline), PRKCA was up-regulated in mDCs and pDCs post vaccination with FluMist. No change in PRKCA expression was observed in PMBCs, monocytes, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PTGS2 response
    • Description: Compared to Day 0 (baseline), PTGS2 was down-regulated in PMBCs but up-regulated in monocytes and mDCs at Day 7 post vaccination with FluMist. No change in PTGS2 expression was observed in B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host REL response
    • Description: Compared to Day 0 (baseline), REL was down-regulated in PMBCs and monocytes at Day 7 post vaccination with FluMist. No change in REL expression was observed in mDCs, pDCs, or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SIRPA response
    • Description: Compared to Day 0 (baseline), SIRPA was down-regulated in monocytes post vaccination with FluMist. No change in SIRPA expression was observed in PMBCs, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SOCS3 response
    • Description: Compared to Day 0 (baseline), SOCS3 was down-regulated in PMBCs and monocytes but up-regulated in mDCs at Day 7 post vaccination with FluMist. No change in SOCS3 expression was observed in pDCs or B cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STAT6 response
    • Description: Compared to Day 0 (baseline), STAT6 was up-regulated in pDCs post vaccination with FluMist. No change in STAT6 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TCF7L2 response
    • Description: Compared to Day 0 (baseline), TCF7L2 was up-regulated in pDCs post vaccination with FluMist. No change in TCF7L2 expression was observed in PMBCs, monocytes, mDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TFRC response
    • Description: Compared to Day 0 (baseline), TFRC was down-regulated in PMBCs, mDCs, and B-cells at Day 7 post vaccination with FluMist. No change in TFRC expression was observed in monocytes or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TGFB1 response
    • Description: Compared to Day 0 (baseline), TGFB1 was down-regulated in monocytes post vaccination with FluMist. No change in TGFB1 expression was observed in PMBCs, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TGFBR2 response
    • Description: Compared to Day 0 (baseline), TGFBR2 was up-regulated in mDCs post vaccination with FluMist. No change in TGFBR2 expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TICAM1 response
    • Description: Compared to Day 0 (baseline), TICAM1 was down-regulated in mDCs post vaccination with FluMist. No change in TICAM1 expression was observed in PMBCs, monocytes, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR6 response
    • Description: Compared to Day 0 (baseline), TLR6 was up-regulated in mDCs and pDCs post vaccination with FluMist. No change in TLR6 expression was observed in PMBCs, monocytes, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR7 response
    • Description: Compared to Day 0 (base line), TLR7 was up-regulated in PMBCs and pDCs but was down-regulated in B-cells at Day 7 post vaccination with FluMist. No change in TLR7 expression was observed in monocytes or mDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: Compared to Day 0 (baseline), TLR8 was up-regulated in monocytes and mDCs but down-regulated in pDCs post vaccination with FluMist. No change in TLR8 expression was observed in PMBCs or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNF response
    • Description: Compared to Day 0 (baseline), TNF was up-regulated in monocytes post vaccination with FluMist. No change in TNF expression was observed in PMBCs, monocytes, mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFAIP3 response
    • Description: Compared to Day 0 (baseline), TNFAIP3 was down-regulated in PMBCs and B-cells but up-regulated in monocytes at Day 7 post vaccination with FluMist. No change in TNFAIP3 expression was observed in mDCs or pDCs at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF10 response
    • Description: Compared to Day 0 (baseline), TNFSF10 was up-regulated in PMBCs and monocytes post vaccination with FluMist. No change in TNSFSF10 expression was observed in mDCs, pDCs, or B-cells at Day 7 post vaccination with FluMist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Flumist was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011). The following host responses are UP regulated gene expressions which experienced at least .33 fold increase in expression.
  • Host ACER3 response
    • Description: Compared to Day 0, ACER3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host AHCYL1 response
    • Description: Compared to Day 0, AHCYL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ALDH1A1 response
    • Description: Compared to Day 0, ALDH1A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host APOBEC3F response
    • Description: Compared to Day 0, APOBEC3F was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host APOBEC3G response
    • Description: Compared to Day 0, APOBEC3G was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ARMC10 response
    • Description: Compared to Day 0, ARMC10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ARMC10 response
    • Description: Compared to Day 0, ARMC10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ATP6V1B2 response
    • Description: Compared to Day 0, ATP6V1B2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ATP6V1C1 response
    • Description: Compared to Day 0, ATP6V1C1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011). ATP6V1C1
    • Detailed Gene Information: Click Here.
  • Host C14orf119 response
    • Description: Compared to Day 0, C14orf119 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C15orf29 response
    • Description: Compared to Day 0, C15orf29 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host C3orf1 response
    • Description: Compared to Day 0, C3orf1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CACNA2D3 response
    • Description: Compared to Day 0, CACNA2D3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CALHM2 response
    • Description: Compared to Day 0, CALHM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CASP1 response
    • Description: Compared to Day 0, CASP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CBFA2T2 response
    • Description: Compared to Day 0, CBFA2T2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CBR4 response
    • Description: Compared to Day 0, CBR4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCDC56 response
    • Description: Compared to Day 0, CCDC56 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCDC88A response
    • Description: Compared to Day 0, CCDC88A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCND3 response
    • Description: Compared to Day 0, CCND3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CCR2 response
    • Description: Compared to Day 0, CCR2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD14 response
    • Description: Compared to Day 0, CD14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD163 response
    • Description: Compared to Day 0, CD163 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD1D response
    • Description: Compared to Day 0, CD1D was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD2 response
    • Description: Compared to Day 0, CD2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD27 response
    • Description: Compared to Day 0, CD27 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD33 response
    • Description: Compared to Day 0, CD33 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CD36 response
    • Description: Compared to Day 0, CD36 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CDC14A response
    • Description: Compared to Day 0, CDC14A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CHST15 response
    • Description: Compared to Day 0, CHST15 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CLEC12A response
    • Description: Compared to Day 0, CLEC 12A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CNDP2 response
    • Description: Compared to Day 0, CNDP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host COPB2 response
    • Description: Compared to Day 0, COPB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CREBZF response
    • Description: Compared to Day 0, CREBZF was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CRLS1 response
    • Description: Compared to Day 0, CRLS1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CRYZL1 response
    • Description: Compared to Day 0, CRYZL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CSF1R from humans response
    • Description: Compared to Day 0, CSF1R was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CTBP2 response
    • Description: Compared to Day 0, CTBP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CX3CR1 response
    • Description: Compared to Day 0, CX3CR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CYBB response
    • Description: Compared to Day 0, CYBB was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host CYFIP1 response
    • Description: Compared to Day 0, CYFIP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DCAF7 response
    • Description: Compared to Day 0, DCAF7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DDX19A response
    • Description: Compared to Day 0, DDX19A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DDX60 response
    • Description: Compared to Day 0, DDX60 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DENND2D response
    • Description: Compared to Day 0, DENND2D was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DNAJC24 response
    • Description: Compared to Day 0, DNAJC24 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DPYD response
    • Description: Compared to Day 0, DPYD was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DPYSL2 response
    • Description: Compared to Day 0, DPYSL2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host DYNC1I2 response
    • Description: Compared to Day 0, DYNC1I2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EAF2 response
    • Description: Compared to Day 0, EAF2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ECHDC1 response
    • Description: Compared to Day 0, ECHDC1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EDEM3 response
    • Description: Compared to Day 0, EDEM3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EEA1 response
    • Description: Compared to Day 0, EEA1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EIF2S1 response
    • Description: Compared to Day 0, EIF2S1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ELAVL1 response
    • Description: Compared to Day 0, ELAVL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ELP3 response
    • Description: Compared to Day 0, ELP3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EOMES response
    • Description: Compared to Day 0, EOMES was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ETNK1 response
    • Description: Compared to Day 0, ETNK1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host EVL response
    • Description: Compared to Day 0, EVL was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FAM198B response
    • Description: Compared to Day 0, FAM198B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FCGR1B response
    • Description: Compared to Day 0, FCGR1B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FGD2 response
    • Description: Compared to Day 0, FGD2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FGD4 response
    • Description: Compared to Day 0, FGD4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FGL2 response
    • Description: Compared to Day 0, FGL2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FKBP15 response
    • Description: Compared to Day 0, FKBP15 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FKBP5 response
    • Description: Compared to Day 0, FKBP5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host FYN response
    • Description: Compared to Day 0, FYN was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host G3BP1 response
    • Description: Compared to Day 0, G3BP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GAPT response
    • Description: Compared to Day 0, GAPT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GGPS1 response
    • Description: Compared to Day 0, GGPS1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP1 response
    • Description: Compared to Day 0, GIMAP1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP4 response
    • Description: Compared to Day 0, GIMAP4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP6 response
    • Description: Compared to Day 0, GIMAP6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GIMAP8 response
    • Description: Compared to Day 0, GIMAP8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GPBAR1 response
    • Description: Compared to Day 0, GPBAR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GPR171 response
    • Description: Compared to Day 0, GPR171 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GTF2H1 response
    • Description: Compared to Day 0, GTF2H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host GUSBP3 response
    • Description: Compared to Day 0, GUSBP3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HCK response
    • Description: Compared to Day 0, HCK was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HECA response
    • Description: Compared to Day 0, HECA was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HERC4 response
    • Description: Compared to Day 0, HERC4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HIST1H1D response
    • Description: Compared to Day 0, HIST1H1D was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HIST1H2BG response
    • Description: Compared to Day 0, HIST1H2BG was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HNMT response
    • Description: Compared to Day 0, HNMT was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host HSD17B4 response
    • Description: Compared to Day 0, HSD17B4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host human STAT1 response
    • Description: Compared to Day 0, STAT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ICAM2 response
    • Description: Compared to Day 0, ICAM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IDH1 response
    • Description: Compared to Day 0, IHD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFI16 response
    • Description: Compared to Day 0, IFI16 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IFI35 response
    • Description: Compared to Day 0, IFI35 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IKZF1 response
    • Description: Compared to Day 0, IKZF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL7R response
    • Description: Compared to Day 0, IL7R was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IRAK3 response
    • Description: Compared to Day 0, IRAK3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JAK2 response
    • Description: Compared to Day 0, JAK2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host JUN response
    • Description: Compared to Day 0, JUN was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KCNE3 response
    • Description: Compared to Day 0, KCNE3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KCTD12 response
    • Description: Compared to Day 0, KCTD12 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KIAA0907 response
    • Description: Compared to Day 0, KIAA0907 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLF6 response
    • Description: Compared to Day 0, KLF6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLF6 response
    • Description: Compared to Day 0, KLF6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLHL6 response
    • Description: Compared to Day 0, KLHL6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLRD1 response
    • Description: Compared to Day 0, KLRD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KLRG1 response
    • Description: Compared to Day 0, KLRG1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KRCC1 response
    • Description: Compared to Day 0, KRCC1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host KRIT1 response
    • Description: Compared to Day 0, KRIT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LILRB1 response
    • Description: Compared to Day 0, LILRB1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100131541 response
    • Description: Compared to Day 0, LOC100131541 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100131993 response
    • Description: Compared to Day 0, LOC100131993 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100170939 response
    • Description: Compared to Day 0, LOC100170939 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100288387 response
    • Description: Compared to Day 0, LOC100288387 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC100288939 response
    • Description: Compared to Day 0, LOC100288939 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC144571 response
    • Description: Compared to Day 0, LOC144571 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC150166 response
    • Description: Compared to Day 0, LOC150166 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LOC284837 response
    • Description: Compared to Day 0, LOC284837 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LPXN response
    • Description: Compared to Day 0, LPXN was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host LRRC8D response
    • Description: Compared to Day 0, LRRC8D was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host M6PR response
    • Description: Compared to Day 0, M6PR was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAP4K4 response
    • Description: Compared to Day 0, MAP4K4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MARCH1 response
    • Description: Compared to Day 0, MARCH1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MAVS response
    • Description: Compared to Day 0, MAVS was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MEF2C response
    • Description: Compared to Day 0, MEF2C was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MEGF9 response
    • Description: Compared to Day 0, MEGF9 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MESDC2 response
    • Description: Compared to Day 0, MESDC2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host METTL3 response
    • Description: Compared to Day 0, METTL3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host METTL7A response
    • Description: Compared to Day 0, METTL7A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MFSD8 response
    • Description: Compared to Day 0, MFSD8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MGAT2 response
    • Description: Compared to Day 0, MGAT2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MGST1 response
    • Description: Compared to Day 0, MGST1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MITD1 response
    • Description: Compared to Day 0, MITD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MKKS response
    • Description: Compared to Day 0, MKKS was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MLLT3 response
    • Description: Compared to Day 0, MLLT3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MNDA response
    • Description: Compared to Day 0, MNDA was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MON2 response
    • Description: Compared to Day 0, MON2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MOSPD2 response
    • Description: Compared to Day 0, MOSPD2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MPEG1 response
    • Description: Compared to Day 0, MPEG1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MRPS31 response
    • Description: Compared to Day 0, MRPS31 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A14 response
    • Description: Compared to Day 0, MS4A14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A4A response
    • Description: Compared to Day 0, MS4A4A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A6A response
    • Description: Compared to Day 0, MS4A6A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MS4A7 response
    • Description: Compared to Day 0, MS4A7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MTIF3 response
    • Description: Compared to Day 0, MTIF3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MX1 response
    • Description: Compared to Day 0, MX1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host MYOF response
    • Description: Compared to Day 0, MYOF was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NAGA response
    • Description: Compared to Day 0, NAGA was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NAGK response
    • Description: Compared to Day 0, NAGK was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NAIP response
    • Description: Compared to Day 0, NAIP was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NCOR1 response
    • Description: Compared to Day 0, NCOR1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NDUFA8 response
    • Description: Compared to Day 0, NDUFA8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NEK7 response
    • Description: Compared to Day 0, NEK7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NFATC3 response
    • Description: Compared to Day 0, NFATC3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NSUN5 response
    • Description: Compared to Day 0, NSUN5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NSUN5P1 response
    • Description: Compared to Day 0, NSUN5P1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NSUN5P2 response
    • Description: Compared to Day 0, NSUN5P2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NUMB response
    • Description: Compared to Day 0, NUMB was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NUP210 response
    • Description: Compared to Day 0, NUP210 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host NUP43 response
    • Description: Compared to Day 0, NUP43 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS1 response
    • Description: Compared to Day 0, OAS1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS2 response
    • Description: Compared to Day 0, OAS2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OAS3 response
    • Description: Compared to Day 0, OAS3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host OSBPL11 response
    • Description: Compared to Day 0, OSBPL11 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PCMT1 response
    • Description: Compared to Day 0, PCMT1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PHF14 response
    • Description: Compared to Day 0, PHF14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PID1 response
    • Description: Compared to Day 0, PID1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PION response
    • Description: Compared to Day 0, PION was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PLXNB2 response
    • Description: Compared to Day 0, PLXNB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PMS1 response
    • Description: Compared to Day 0, PMS1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POC5 response
    • Description: Compared to Day 0, POC5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host POLK response
    • Description: Compared to Day 0, POLK was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PSEN1 response
    • Description: Compared to Day 0, PSEN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PTGDR response
    • Description: Compared to Day 0, PTGDR was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host PYCARD response
    • Description: Compared to Day 0, PYCARD was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host QKI response
    • Description: Compared to Day 0, QKI was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RAB10 response
    • Description: Compared to Day 0, RAB10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RALA response
    • Description: Compared to Day 0, RALA was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RASSF4 response
    • Description: Compared to Day 0, RASSF4 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNASE2 response
    • Description: Compared to Day 0, RNASE2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNASE6 response
    • Description: Compared to Day 0, RNASE6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNF170 response
    • Description: Compared to Day 0, RNF170 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RNF213 response
    • Description: Compared to Day 0, RNF213 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ROCK2 response
    • Description: Compared to Day 0, ROCK2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host RTN1 response
    • Description: Compared to Day 0, RTN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host S100PBP response
    • Description: Compared to Day 0, S100PBP was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SAMD3 response
    • Description: Compared to Day 0, SAMD3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SAMD9L response
    • Description: Compared to Day 0, SAMD9L was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SAMHD1 response
    • Description: Compared to Day 0, SAMHD1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SAP30 response
    • Description: Compared to Day 0, SAP30 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SETDB2 response
    • Description: Compared to Day 0, SETDB2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SETX response
    • Description: Compared to Day 0, SETX was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SGK223 response
    • Description: Compared to Day 0, SGK223 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SGMS2 response
    • Description: Compared to Day 0, SGMS2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF6 response
    • Description: Compared to Day 0, SLAMF6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLAMF7 response
    • Description: Compared to Day 0, SLAMF7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLC25A40 response
    • Description: Compared to Day 0, SLC25A40 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLC35A1 response
    • Description: Compared to Day 0, SLC35A1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SLC35B3 response
    • Description: Compared to Day 0, SLC35B3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SNORA28 response
    • Description: Compared to Day 0, SNORA28 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SNX1 response
    • Description: Compared to Day 0, SNX1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SON response
    • Description: Compared to Day 0, SON was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SOS1 response
    • Description: Compared to Day 0, SOS1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPN response
    • Description: Compared to Day 0, SPN was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SPTLC2 response
    • Description: Compared to Day 0, SPTLC2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SRGAP2 response
    • Description: Compared to Day 0, SRGAP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ST6GAL1 response
    • Description: Compared to Day 0, ST6GAL1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STK17B response
    • Description: Compared to Day 0, STK17B was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STK38 response
    • Description: Compared to Day 0, STK38 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host STX7 response
    • Description: Compared to Day 0, STX7 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SUV420H1 response
    • Description: Compared to Day 0, SUV420H1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host SYNRG response
    • Description: Compared to Day 0, SYNRG was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TARP response
    • Description: Compared to Day 0, TARP was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TBC1D8 response
    • Description: Compared to Day 0, TBC1D8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TCF7L2 response
    • Description: Compared to Day 0, TCF7L2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TFCP2 response
    • Description: Compared to Day 0, TFCP2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TFEC response
    • Description: Compared to Day 0, TFEC was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host THYN1 response
    • Description: Compared to Day 0, THYN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TIA1 response
    • Description: Compared to Day 0, TIA1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TICAM2 response
    • Description: Compared to Day 0, TICAM2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR5 from humans response
    • Description: Compared to Day 0, TLR5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR8 response
    • Description: Compared to Day 0, TLR8 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TMEM63A response
    • Description: Compared to Day 0, TMEM63A was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TMEM69 response
    • Description: Compared to Day 0, TMEM69 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNFSF10 response
    • Description: Compared to Day 0, TNFSF10 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRAF3IP3 response
    • Description: Compared to Day 0, TRAF3IP3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRGC2 response
    • Description: Compared to Day 0, TRGC2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TRIM14 response
    • Description: Compared to Day 0, TRIM14 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TTC17 response
    • Description: Compared to Day 0, TTC17 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host UBE2L3 response
    • Description: Compared to Day 0, UBE2L3 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host UBN2 response
    • Description: Compared to Day 0, UBN2 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host USO1 response
    • Description: Compared to Day 0, USO1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host UTP6 response
    • Description: Compared to Day 0, UTP6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VCAN response
    • Description: Compared to Day 0, VCAN was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VPS35 response
    • Description: Compared to Day 0, VPS35 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VPS45 response
    • Description: Compared to Day 0, VPS45 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host VPS72 response
    • Description: Compared to Day 0, VPS72 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host XAF1 response
    • Description: Compared to Day 0, XAF1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host XPO1 response
    • Description: Compared to Day 0, XPO1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZFAND5 response
    • Description: Compared to Day 0, ZFAND5 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZKSCAN1 response
    • Description: Compared to Day 0, ZKSCAN1 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZMYM6 response
    • Description: Compared to Day 0, ZMYM6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF207 response
    • Description: Compared to Day 0, ZNF207 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF573 response
    • Description: Compared to Day 0, ZNF573 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZNF638 response
    • Description: Compared to Day 0, ZNF638 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host ZSWIM6 response
    • Description: Compared to Day 0, ZSWIM6 was UP regulated in PBMCs in Homo Sapiens on Day 3 or Day 7 after vaccination with Flumist (Nakaya et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Since 1991 an annual clinical study has been conducted in the
    UK in healthy adults aged 18 years or older (FDA: Fluvirin).
  • Immune Response: In the adult group, for all antigens (A/H1N1, A/H3N2 and B) at least one of the following point estimate criteria was met: the proportion of subjects with seroconversion (post-vaccination titer ≥1:40 from a pre-vaccination titer <1:10) or significant increase (at least a four-fold increase from pre-vaccination titer ≥1:10) in antibody titer was greater than 40%; the geometric mean titer (GMT) increase was >2.5; the proportion of subjects with a post-vaccination hemagglutination inhibition (HI) antibody titer ≥1:40 was greater than 70% (FDA: Fluvirin).
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: A placebo-controlled study of adults ranging in ages 19 to 59 and on a geriatric population ranging in ages 61 to 86 years of age was carried out in the United States. An administration of a single-dose of 1999-2000 formulation of the FLUZONE vaccine was given to all test subjects (FDA: Fluzone).
  • Immune Response: In the adult and geriatric popolution, serum hemagglutination-inhibiting (HI) antibody responses to FLUZONE were significantly higher after immunization for all three virus strains (HiNi, H3N2, and B) (FDA: Fluzone).
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Placebo-controlled trials demonstrate that among older persons and healthy young adults, administration of FLUZONE is not associated with higher rates of systemic symptoms (i.e fever, malaise, myalgia, and headache) when compared with placebo injections (FDA: Fluzone). The most frequent side effects of FLUZONE are soreness at the injection site, local pain and swelling. These symptoms were recorded as lasting less than two days after injection of the vaccine. Other symptoms include fever, malaise, myalgia, and other systemic symptoms most likely prompted by the subject not having prior exposure to the vaccine (FDA: Fluzone).

Human Response

  • Vaccination Protocol: A clinical study was conducted in healthy children ranging in ages 6 to 36 months of age using two doses one month apart of the 2003-2004 formulation of FLUZONE vaccine.
  • Immune Response: The FLUZONE vaccine administered in the children had similar proportions of immune responses as those that were in adults.
  • Side Effects: Side effects of the FLUZONE injection in these children included: local reactions such a pain at injection site and swelling. Most of the local and systemic reactions were mild and were similiar in proportion to reactions observed in adults. The only side effect that required intervention was analgesics.

Human Response

  • Vaccination Protocol: A study of 2 doses one month apart of Fluzone (2003-2004) in 31 healthy children 6-36 months of age (FDA: Fluzone).
  • Immune Response: In a study of 2 doses one month apart of Fluzone (2003-2004) in 31 healthy children 6-36 months of age, 77%, 77%, and 48% achieved post vaccination HI titers of 1:40 or greater for the A/H1, A/H3, and B strains, respectively (FDA: Fluzone).
  • Immune Response Assay Type: HI antibody assay

Human Response

  • Vaccination Protocol: A total of 3,876 individuals 65 years of age and older were randomized to receive either Fluzone High-Dose or Fluzone in a phase 3, multi-center, randomized, active-controlled, double blind trial conducted in the US (FDA: Fluzone).
  • Immune Response: Statistically superior HI titers after vaccination with Fluzone High-Dose compared to standard dose Fluzone were demonstrated for two of the three influenza strains (FDA: Fluzone).

Human Response

  • Vaccination Protocol: A total of 3,876 individuals 65 years of age and older were randomized to receive either Fluzone High-Dose or Fluzone in a phase 3, multi-center, randomized, active-controlled, double blind trial conducted in the US (FDA: Fluzone).
  • Immune Response: Statistically superior HI titers after vaccination with Fluzone High-Dose compared to standard dose Fluzone were demonstrated for two of the three influenza strains (FDA: Fluzone).

Human Response

  • Side Effects: The most common side affects are mild hypersensitivity reactions such as rash, local reactions at the injection site and influenza like symptoms (FDA: H1N1 Novartis Vaccine).

Human Response

  • Side Effects: Most common side effects were soreness at the injection site, tenderness, pain and swelling. Common systemic side effects are malaise, headache and myalgia (FDA: H1N1 Vaccine Sanofi Pasteur).

Human Response

  • Vaccination Protocol: DNA vaccine encoding H5 as a priming vaccine (prime) followed by an H5N1 monovalent inactivated vaccine (MIV; boost) (Ledgerwood et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: In the two studies, DNA priming with a 24-week monovalent inactivated vaccine (MIV) boost interval induced protective HAI titres in 21 (81%) of 26 of individuals, with an increase in geometric mean titre (GMT) of more than four times that of individuals given the MIV-MIV regimen at 4 or 24 weeks (GMT 103-206 vs GMT 27-33). Additionally, neutralising antibodies directed to the conserved stem region of H5 were induced by this prime-boost regimen in several individuals (Ledgerwood et al., 2011).
  • Efficacy: DNA priming 24 weeks in advance of influenza vaccine boosting increased the magnitude of protective antibody responses (HAI) and in some cases induced haemagglutinin-stem-specific neutralising antibodies. A DNA-MIV vaccine regimen could enhance the efficacy of H5 or other influenza vaccines and shows that anti-stem antibodies can be elicited by vaccination in man (Ledgerwood et al., 2011).

Human Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Vaccination was safe and well-tolerated and elicited protection from challenge in approximately 50% of subjects, providing the first proof-of-principle of a DNA vaccine affording protection in humans (Loudon et al., 2010).

Human Response

  • Vaccination Protocol: A randomized, placebo-controlled, double-blind, clinical trial was conducted in healthy adults ranging in ages 18 through 64 in the United States. The subjects received an injection of the vaccine formulation A/Vietnam/1203/2004 (H5N1, clade 1), followed by another dose of the same formulation 28 days later
  • Immune Response Assay Type: HI antibody assay
  • Side Effects: Most side effects were mild and included pain, tenderness, redness and swelling of the injection site. These local effects were resolved in three days after vaccination. Systemic reactions due to vaccination were also mild to moderately severe.

Baboon Response

  • Vaccination Protocol: Fluarix was used to vaccinate young healthy human subjects at the age of 18-50 years old. Blood samples were collected from the vaccinees on days 0, 3, and 7 after vaccination. Influenza hemagglutination inhibition assay (HAI) was performed. The peripheral blood mononuclear cells (PBMCs) were isolated. Different cell populations were isolated by flow cytometer. Microarray experiment was then performed using the PBMC samples (Nakaya et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
References References References References References References References References References References References References References References References
Bucasas et al., 2011: Bucasas KL, Franco LM, Shaw CA, Bray MS, Wells JM, Niño D, Arden N, Quarles JM, Couch RB, Belmont JW. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. The Journal of infectious diseases. 2011; 203(7); 921-929. [PubMed: 21357945].
Hoek et al., 2015: Hoek KL, Samir P, Howard LM, Niu X, Prasad N, Galassie A, Liu Q, Allos TM, Floyd KA, Guo Y, Shyr Y, Levy SE, Joyce S, Edwards KM, Link AJ. A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. PloS one. 2015; 10(2); e0118528. [PubMed: 25706537].
FDA: Afluria: FDA: Afluria influenza virus vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094043.htm]
FDA: Agriflu: FDA: Agriflu [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm192126.htm]
FDA: Fluarix: FDA: Fluarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112850.htm]
GSK: US Fluarix: GSK: US Fluarix vaccine information [http://us.gsk.com/products/assets/us_fluarix.pdf]
Nakaya et al., 2011: Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B. Systems biology of vaccination for seasonal influenza in humans. Nature immunology. 2011; 12(8); 786-795. [PubMed: 21743478].
FDA: FluLaval: FDA FluLaval information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112845.htm]
Block et al., 2008: Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008; 26(38); 4940-4946. [PubMed: 18662737].
FDA: Flumist: FDA: Flumist Influenza Virus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094047.htm]
FluMist website: FluMist official website [http://www.flumist.com/]
Nakaya et al., 2011: Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B. Systems biology of vaccination for seasonal influenza in humans. Nature immunology. 2011; 12(8); 786-795. [PubMed: 21743478].
FDA: Fluvirin: FDA: Fluvirin Influenza Virus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112852.htm]
FDA: Fluzone: FDA: Fluzone influenza vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm]
FDA: Fluzone: FDA: Fluzone influenza vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm]
FDA: H1N1 Novartis Vaccine: FDA H1N1 Influenza Vaccine from Novartis Vaccines and Diagnostics Ltd [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm]
FDA: H1N1 Vaccine Sanofi Pasteur: FDA: H1N1 Influenza virus vaccine from Sanofi Pasteur [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm]
Ledgerwood et al., 2011: Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. The Lancet infectious diseases. 2011; 11(12); 916-924. [PubMed: 21975270].
Loudon et al., 2010: Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, Franchini AM, Fuller JT, White PA, Nyuandi J, Wiley CA, Murphey-Corb M, Fuller DH. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PloS one. 2010; 5(6); e11021. [PubMed: 20544035].
Pertmer et al., 2001: Pertmer TM, Oran AE, Madorin CA, Robinson HL. Th1 genetic adjuvants modulate immune responses in neonates. Vaccine. 2001; 19(13-14); 1764-1771. [PubMed: 11166902].
FDA: Sanofi Pasteur H5N1: FDA: Sanofi Pasteur H5N1Influenza virus vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094044.htm]